International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS

International differences in management/outcomes among patients with type 2 diabetes and heart failure (HF) are not well characterized. We sought to evaluate geographic variation in treatment and outcomes among these patients. Among 14,671 participants in the Trial Evaluating Cardiovascular Outcomes...

Full description

Saved in:
Bibliographic Details
Published in:The American heart journal 2019-12, Vol.218, p.57-65
Main Authors: Bhatt, Ankeet S., Luo, Nancy, Solomon, Nicole, Pagidipati, Neha J., Ambrosio, Giuseppe, Green, Jennifer B., McGuire, Darren K., Standl, Eberhard, Cornel, Jan H., Halvorsen, Sigrun, Lopes, Renato D., White, Harvey D., Holman, Rury R., Peterson, Eric D., Mentz, Robert J.
Format: Article
Language:English
Subjects:
Adrenergic beta-Antagonists - therapeutic use
Aged
Angiotensin-converting enzyme inhibitors
Angiotensin-Converting Enzyme Inhibitors - therapeutic use
Asia
Cardiovascular disease
Cause of Death
Clinical outcomes
Clinical trials
Comorbidity
Congestive heart failure
Coronary vessels
Diabetes
Diabetes mellitus
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2 - complications
Diabetes Mellitus, Type 2 - drug therapy
Diabetes Mellitus, Type 2 - mortality
Diuretics - therapeutic use
Double-Blind Method
Enrollments
Enzyme inhibitors
Europe
Evaluation
Female
Follow-Up Studies
Geographical variations
Health hazards
Heart failure
Heart Failure - complications
Heart Failure - drug therapy
Heart Failure - mortality
Hemoglobin
Hospitalization
Humans
Hypoglycemic Agents - therapeutic use
Kaplan-Meier Estimate
Latin America
Male
Middle Aged
Mortality
North America
Patients
Peptidyl-dipeptidase A
Proportional Hazards Models
Sitagliptin Phosphate - therapeutic use
Stroke Volume
Subgroups
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:International differences in management/outcomes among patients with type 2 diabetes and heart failure (HF) are not well characterized. We sought to evaluate geographic variation in treatment and outcomes among these patients. Among 14,671 participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS), those with HF at baseline and a documented ejection fraction (EF) (N = 1591; 10.8%) were categorized by enrollment region (North America, Latin America, Western Europe, Eastern Europe, and Asia Pacific). Cox models were used to examine the association between geographic region and the primary outcome of all-cause mortality (ACM) or hospitalization for HF (hHF) in addition to ACM alone. Analyses were stratified by those with EF
ISSN:0002-8703
1097-6744
DOI:10.1016/j.ahj.2019.08.016